-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Immix Biopharma, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2021 to Q3 2024.
- Immix Biopharma, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $11.1K, a 63.7% increase year-over-year.
- Immix Biopharma, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $38.3K, a 62.6% increase year-over-year.
- Immix Biopharma, Inc. annual Income Tax Expense (Benefit) for 2023 was $26.4K, a 157% increase from 2022.
- Immix Biopharma, Inc. annual Income Tax Expense (Benefit) for 2022 was $10.3K, a 70.8% increase from 2021.
- Immix Biopharma, Inc. annual Income Tax Expense (Benefit) for 2021 was $6.01K, a 65.7% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)